ZA991951B - Compound and its use. - Google Patents

Compound and its use.

Info

Publication number
ZA991951B
ZA991951B ZA9901951A ZA991951A ZA991951B ZA 991951 B ZA991951 B ZA 991951B ZA 9901951 A ZA9901951 A ZA 9901951A ZA 991951 A ZA991951 A ZA 991951A ZA 991951 B ZA991951 B ZA 991951B
Authority
ZA
South Africa
Prior art keywords
compound
Prior art date
Application number
ZA9901951A
Other languages
English (en)
Inventor
Lorraine Mary Edmeades
Derek Anthony Hill
Terence William Packham
Nigel Arthur Griffith-Skinner
Graham Thronton Hill
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA991951(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA991951B publication Critical patent/ZA991951B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA9901951A 1998-06-10 1999-03-10 Compound and its use. ZA991951B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
ZA991951B true ZA991951B (en) 1999-08-16

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901951A ZA991951B (en) 1998-06-10 1999-03-10 Compound and its use.

Country Status (31)

Country Link
US (1) US6333198B1 (de)
EP (2) EP0963980B1 (de)
JP (1) JP2989189B1 (de)
KR (1) KR100322354B1 (de)
CN (2) CN1238454A (de)
AP (3) AP0102286A0 (de)
AR (1) AR014074A1 (de)
AT (1) ATE218552T1 (de)
AU (1) AU2031999A (de)
BR (1) BR9900984A (de)
CA (1) CA2265194C (de)
DE (1) DE69901656T2 (de)
DK (1) DK0963980T3 (de)
EA (1) EA000666B1 (de)
ES (1) ES2178342T3 (de)
GB (1) GB9812413D0 (de)
HR (1) HRP990074A2 (de)
HU (1) HUP9900592A3 (de)
ID (1) ID22957A (de)
MA (1) MA24777A1 (de)
NO (2) NO991151L (de)
NZ (1) NZ334590A (de)
PE (1) PE20000332A1 (de)
PL (1) PL331870A1 (de)
PT (1) PT963980E (de)
SG (1) SG85628A1 (de)
SI (1) SI0963980T1 (de)
TR (1) TR199900520A3 (de)
UY (1) UY25946A1 (de)
YU (1) YU12399A (de)
ZA (1) ZA991951B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
MXPA03005886A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado de aspartato de amlodipina como antagonista del canal de calcio.
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
WO2002053538A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine fumarate
BR0116552A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
GB2371862B (en) * 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
WO2002053542A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Process for making amlodipine maleate
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
EP1562912A2 (de) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Verfahren zur herstellung von rosuvastatin-calcium
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP1708708A1 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-freie säure-polymorphen
EP1709002A2 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-natrium-polymorphe
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
MXPA06012220A (es) * 2004-04-21 2007-07-18 Teva Pharma Procesos para preparar sodio de montelukast.
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105769A2 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
EP1687254A2 (de) * 2004-06-28 2006-08-09 Teva Pharmaceutical Fine Chemicals S.R.L. Verfahren zur optischen trennung und rückgewinnung von tomoxetin
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
TW200611692A (en) * 2004-07-20 2006-04-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
EP1768949A2 (de) * 2004-07-22 2007-04-04 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphe von atomoxetien-hydrochlorid
CN101068814A (zh) * 2004-09-04 2007-11-07 特瓦制药工业有限公司 分离的伐昔洛韦杂质，制备伐昔洛韦杂质的方法及其作为参比标准物的应用
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
MX2007003652A (es) * 2004-09-28 2009-02-16 Teva Pharma Proceso para preparar formas de calcio de atorvastatina sustancialmente libre de impurezas.
CA2582090A1 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
SI1836157T1 (sl) * 2005-01-11 2009-12-31 Teva Pharm Fine Chemicals Srl Postopek priprave 1-amino-3,5-dimetiladamantan hidroklorida
EP1851206B1 (de) 2005-02-22 2012-08-15 Teva Pharmaceutical Industries, Ltd. Rosuvastatin und seine salze die frei von rosuvastatin-alkylether sind und ein verfahren zu ihrer herstellung
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
WO2006091731A2 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
CA2599478A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the purification of duloxetine hydrochloride
JP2008501721A (ja) * 2005-04-05 2008-01-24 テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ 安定性アトモキセチン塩酸塩、その調製方法及びその安定性の分析的調節
MX2007012396A (es) * 2005-04-06 2007-11-20 Teva Pharma Formas cristalinas de pregabalina.
CA2603215A1 (en) * 2005-04-11 2006-10-19 Teva Pharmaceutical Industries Ltd. Process for making (s)-pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
WO2006113425A1 (en) * 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CA2604602A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
EP1879852A1 (de) * 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Lactamfreies pregabalin und herstellungsverfahren dafür
KR20070067077A (ko) * 2005-05-10 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이소부틸글루타르산을 함유하지 않는 프레가발린 및 이의제조 방법
ATE523484T1 (de) * 2005-05-10 2011-09-15 Teva Pharma Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure
CA2605736A1 (en) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Purification of cinacalcet
CN101208312A (zh) * 2005-06-27 2008-06-25 西科尔公司 用于合成阿那曲唑及纯化一种阿那曲唑中间体的方法
US20070032660A1 (en) * 2005-06-27 2007-02-08 Alessandro Pontiroli Purification process for Anastrozole intermediate
ES2358923T3 (es) * 2005-07-05 2011-05-16 Teva Pharmaceutical Industries, Ltd. Purificación de montelukast.
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
WO2007035890A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
EP1891034A2 (de) * 2005-12-27 2008-02-27 Teva Pharmaceutical Fine Chemicals S.R.L. Verfahren zur herstellung von darifenacin-hydrobromid
CA2644819A1 (en) * 2006-03-27 2007-11-08 Teva Pharmaceutical Fine Chemicals S.R.L. Process for preparing memantine hydrochloride substantially free of impurities
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
WO2007139933A2 (en) * 2006-05-24 2007-12-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
WO2007143152A2 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
BRPI0702897A2 (pt) * 2006-05-31 2011-03-15 Teva Pharmaceutical Ind Ltda processo para preparar um intermediário de pregabalina
ES2339297T3 (es) * 2006-06-29 2010-05-18 Ivax Pharmaceuticals S.R.O. Regulacion de la produccion de metabolitos acidos.
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CA2659290A1 (en) * 2006-08-14 2008-02-21 Jean-Paul Roduit A process for the preparation of lamotrigine
EP2139845A1 (de) * 2007-02-26 2010-01-06 Teva Pharmaceutical Industries Ltd. Zwischenprodukte und verfahren zur synthese von ramelteon
EP2021318A2 (de) * 2007-03-22 2009-02-11 Teva Pharmaceutical Industries Ltd. Synthese von (s) - (+)-3-(aminomethyl) -5-methylhexansäure
TW200904982A (en) * 2007-04-11 2009-02-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method for reducing impurity level in mycophenolic acid fermentation
US8084630B2 (en) * 2007-05-31 2011-12-27 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2009046309A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
US8067423B2 (en) * 2007-10-23 2011-11-29 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof
WO2009056993A2 (en) * 2007-11-01 2009-05-07 Teva Pharmaceutical Industries Ltd. A process for the synthesis of ramelteon and its intermediates
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
CA2717580A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
KR20100107500A (ko) * 2008-06-23 2010-10-05 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ) 또는 (ｒ)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US8569371B2 (en) * 2010-03-29 2013-10-29 Pliva Hrvatska D.O.O. Crystal forms of O-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
WO2015092819A2 (en) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR68380B (de) 1979-06-01 1981-12-28 Wellcome Found
EP0021120B1 (de) 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-Diamino-1,2,4-triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische Zusammensetzungen sie enthaltend
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
JPH11501007A (ja) * 1994-12-30 1999-01-26 ザ、ウェルカム、ファンデーション、リミテッド ラモトリジンの製造法
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
UY25946A1 (es) 2000-12-29
DE69901656T2 (de) 2003-01-30
DK0963980T3 (da) 2002-09-16
HU9900592D0 (en) 1999-04-28
NO991151D0 (no) 1999-03-10
HRP990074A2 (en) 2000-10-31
TR199900520A2 (en) 2000-01-21
EP0963980A3 (de) 2000-05-31
ID22957A (id) 1999-12-23
NO20032753D0 (no) 2003-06-17
EP0963980A2 (de) 1999-12-15
CN1238454A (zh) 1999-12-15
HUP9900592A3 (en) 2002-04-29
EA000666B1 (ru) 2000-02-28
KR100322354B1 (ko) 2002-02-07
AP0102286A0 (en) 2000-09-10
NZ334590A (en) 2000-07-28
ES2178342T3 (es) 2002-12-16
BR9900984A (pt) 2000-05-02
CA2265194C (en) 2000-10-10
SI0963980T1 (en) 2002-12-31
JP2989189B1 (ja) 1999-12-13
CN1306210A (zh) 2001-08-01
EA199900159A1 (ru) 1999-12-29
ATE218552T1 (de) 2002-06-15
MA24777A1 (fr) 1999-10-01
AP9901481A0 (en) 1999-03-31
TR199900520A3 (tr) 2000-01-21
KR20000005611A (ko) 2000-01-25
AU2031999A (en) 2000-01-06
EP1170588A1 (de) 2002-01-09
PT963980E (pt) 2002-10-31
YU12399A (sh) 2002-08-12
GB9812413D0 (en) 1998-08-05
PL331870A1 (en) 1999-12-20
JP2000009714A (ja) 2000-01-14
PE20000332A1 (es) 2000-04-10
AR014074A1 (es) 2001-01-31
DE69901656D1 (de) 2002-07-11
AP2001002286A0 (en) 2001-12-31
EP0963980B1 (de) 2002-06-05
HUP9900592A2 (hu) 2000-04-28
SG85628A1 (en) 2002-01-15
NO991151L (no) 1999-12-13
US6333198B1 (en) 2001-12-25
NO20032753L (no) 1999-12-13

Similar Documents

Publication Publication Date Title
ZA991951B (en) Compound and its use.
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
GB9712317D0 (en) Composition, compound and use
GB9818914D0 (en) Use
GB9817235D0 (en) Compound,composition and use
EP1056455A4 (de) Epimorhin-verbindung und dessen verwendung
GB9817236D0 (en) Compound,composition and use
ZA992443B (en) Hydroxy-methyl-hexanones.
GB9718876D0 (en) Compound,composition and use
EP1058550A4 (de) Substituierte semicarbazide und deren verwendung
ZA200006206B (en) Benzazole compounds and their use.
GB9903447D0 (en) Compound, composition and use
ZA993123B (en) Trisresorcinyltriazines.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
GB9817238D0 (en) Compound,composition and use
GB9723859D0 (en) Compound,composition and use
GB9814227D0 (en) The worthybag
GB9807503D0 (en) Use
GB9828004D0 (en) Use
GB9801584D0 (en) The maitriser
HK1028588A1 (en) Case.
GB9723858D0 (en) Compound,composition and use
GB9723856D0 (en) Compound,composition and use
GB9723853D0 (en) Compound, composition and use